These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33587255)

  • 1. Phytochemicals in thyroid cancer: analysis of the preclinical studies.
    Bulotta S; Capriglione F; Celano M; Pecce V; Russo D; Maggisano V
    Endocrine; 2021 Jul; 73(1):8-15. PubMed ID: 33587255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Effect of Various Phytochemicals on Diverse Types of Thyroid Cancers.
    Shin HJ; Hwang KA; Choi KC
    Nutrients; 2019 Jan; 11(1):. PubMed ID: 30634497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond.
    Bulotta S; Celano M; Costante G; Russo D
    Curr Opin Oncol; 2020 Jan; 32(1):13-19. PubMed ID: 31599772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plant natural products with anti-thyroid cancer activity.
    Sharifi-Rad J; Rajabi S; Martorell M; López MD; Toro MT; Barollo S; Armanini D; Fokou PVT; Zagotto G; Ribaudo G; Pezzani R
    Fitoterapia; 2020 Oct; 146():104640. PubMed ID: 32474055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid suppression and radioiodine treatment for differentiated thyroid cancer.
    Rösler H
    Arch Otolaryngol Head Neck Surg; 1987 Jul; 113(7):778-9. PubMed ID: 3580165
    [No Abstract]   [Full Text] [Related]  

  • 6. The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies.
    Iva J; Filip G; Martin B; Pavel Ž; Jan Č
    Klin Onkol; 2018; 31(5):339-344. PubMed ID: 30541319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
    Nilubol N; Merkel R; Yang L; Patel D; Reynolds JC; Sadowski SM; Neychev V; Kebebew E
    Clin Endocrinol (Oxf); 2017 Jan; 86(1):128-133. PubMed ID: 27392538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redifferentiating agents in non-radioiodine avid cancer.
    Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
    Bulotta S; Celano M; Costante G; Russo D
    Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer.
    Braga-Basaria M; Ringel MD
    J Clin Endocrinol Metab; 2003 May; 88(5):1947-60. PubMed ID: 12727938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine in thyroid cancer.
    PATERSON R; WARRINGTON HC; GILBERT CW
    Br Med Bull; 1952; 8(2-3):154-7. PubMed ID: 14935223
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
    Fröhlich E; Wahl R
    Cancer Treat Rev; 2014 Jun; 40(5):665-74. PubMed ID: 24485648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Age of menopause in patients with differentiated thyroid cancer treated with radioiodine].
    Manuel García-Quirós Muñoz J; Martín Hernández T; Torres Cuadro A; Cambil Molina T; Castro Montaño J; Sendón Pérez A
    Endocrinol Nutr; 2010 Mar; 57(3):105-9. PubMed ID: 20304710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of thyroid cancer with radioiodine (I-131).
    FOSTER CG
    Int Rec Med Gen Pract Clin; 1952 Jun; 165(6):361-3. PubMed ID: 14945913
    [No Abstract]   [Full Text] [Related]  

  • 19. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.
    Kebebew E; Lindsay S; Clark OH; Woeber KA; Hawkins R; Greenspan FS
    Thyroid; 2009 Sep; 19(9):953-6. PubMed ID: 19678746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Blockade of iodine in thyroid cancer in known cases. Principles, effectiveness and actual cases].
    Reiners C
    Nuklearmedizin; 2006; 45(3):97-100. PubMed ID: 16710503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.